DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
FDA actions, clinical trial publications, market changes, and editorial corrections. Updated whenever something material happens; new entries within 48 hours.
Lilly’s once-daily oral GLP-1 is approved for weight management; LillyDirect began shipping April 6 at $149/month for the lowest dose.
The largest compounded-semaglutide seller is moving existing patients to FDA-approved medicines.
The list-price cut takes effect January 1, 2027; self-pay prices are unaffected.
A federal price-comparison site that routes cash-pay orders to the manufacturers’ own programs.
A Drug Safety Communication requests removal of the suicidal behavior and ideation warning from GLP-1 receptor agonist medications.
States, plans and manufacturers opt in; Medicaid as early as May 2026, Medicare Part D in January 2027.
Once-daily oral semaglutide 25 mg, with a cardiovascular risk-reduction indication; $149/month self-pay to start.
New patients can pay $199 for their first two months on the starting doses.
For the first time, Ozempic can be bought cash-pay with home delivery through NovoCare Pharmacy.
Novo Nordisk’s first manufacturer cash-pay channel for Wegovy, with home delivery.
Grace periods for compounders ended April 22 (503A) and May 22, 2025 (503B); tirzepatide’s shortage ended December 19, 2024.